Abstract:
:Restless legs syndrome (RLS) is a common neurological movement disorder, characterized by restless and unpleasant sensations in the deep inside of legs. The symptoms of RLS are less noticeable during daytime, but more prevalent at night. Therefore, the disorder can induce low quality of life, insomnia, and impairment of daytime activity. RLS in end-stage renal disease (ESRD) patients is especially problematic due to premature discontinuation of dialysis and increased mortality. The prevalence of RLS among dialysis patients is much higher compared to the prevalence of the same disorder in patients with normal renal functions. Even though there are recommended treatment guidelines for the general population established by Medical Advisory Board of the RLS foundation, which include the use of dopamine agonists, levodopa, gabapentin, benzodiazepines, and opioids, limited information is available on the effects of these therapies in ESRD patients. Since the existing clinical data were extrapolated from small sample sizes in short-term clinical trials, further clinical studies are still needed to better assess the efficacy, safety, and tolerability of these medications in patients with ESRD.
journal_name
CNS Spectrjournal_title
CNS spectrumsauthors
Sahli ZT,Jo J,Mousa SA,Tarazi FIdoi
10.1017/S109285291600064Xsubject
Has Abstractpub_date
2017-02-01 00:00:00pages
14-21issue
1eissn
1092-8529pii
S109285291600064Xjournal_volume
22pub_type
杂志文章,评审相关文献
CNS SPECTRUMS文献大全